Form 4: Redmile Group Reports Acquisition of IGM Biosciences Stock Units as Director Compensation

Redmile Group, through managing director Michael Lee's board service, acquired 828 restricted stock units of IGM Biosciences as part of director compensation.

Summary

• Redmile Group, LLC, a significant shareholder of IGM Biosciences, Inc., reported changes in beneficial ownership.
• On March 31, 2025, Redmile acquired 828 shares of IGM Biosciences common stock in the form of fully vested restricted stock units.
• These units were granted to Michael Lee, a managing director of Redmile and a member of IGM Biosciences' Board of Directors, as part of the company's Outside Director Compensation Policy.
• The acquisition was reported on April 2, 2025.
• Following the transaction, Redmile Group's beneficial ownership in IGM Biosciences stands at 2,964,015 shares.
• Jeremy Green, as the principal of Redmile, also disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The filing indicates continued investment by a major shareholder, but it's a routine transaction related to director compensation.

Positives

• The acquisition of stock units as director compensation aligns the interests of the director with the company's performance.
• Redmile Group maintains a significant ownership stake in IGM Biosciences, demonstrating continued investment.

Management Comments

• Mr. Lee holds these securities as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the securities to Redmile.
• The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any.

Industry Context

This filing is a routine disclosure of changes in beneficial ownership by a major shareholder, Redmile Group, in IGM Biosciences. Such filings are common in the biotech industry, where stock-based compensation is frequently used to incentivize directors and employees.

Comparison to Industry Standards

• Stock grants to board members are a common practice across the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also use stock options and restricted stock units as part of their director compensation packages.
• The amount of stock granted can vary widely based on company size, performance, and board responsibilities.

Related Party Transactions

• The grant of restricted stock units to Michael Lee, a managing director of Redmile Group and a member of IGM Biosciences' Board of Directors, is a related party transaction.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the interests of a director with the company's performance.

Key Dates

Keywords

IGM Biosciences, Redmile Group, beneficial ownership, Form 4, restricted stock units, director compensation, Michael Lee, Jeremy Green